Navigation Links
Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO
Date:5/29/2012

ultiple subsets of interest demonstrated a consistent benefit in the exemestane and entinostat (EE) group versus exemestane and placebo (EP);
  • Sensitivity analysis of baseline characteristics potentially impacting OS did not identify any factors that influenced the effect of EE on OS;
  • Examination of treatments received during follow-up after discontinuation of EE and EP demonstrated balance between treatment group for patients receiving chemotherapy (48% EE: 44% EP), hormone therapy (37% EE: 35% EP), bisphosphonates (2% EE; 0% EP), radiation (6% EE; 5%EP), and surgery (0% EE: 2% EP);
  • Compared to EP, OS was longer in EE group for patients whose first subsequent treatment was a hormone therapy (EE median not reached vs EP median 20.5 months; HR 0.65 [95% CI 0.26, 1.58]) or chemotherapy (EE median 26.9 months vs EP median 17.6 months; HR 0.51 [95% CI 0.25, 1.04])
  • "The metastatic breast cancer community needs new treatment options that can improve survival," said Joanna Horobin, MD, president of Syndax.  "We are hopeful that the positive data we have seen so far in the randomized, phase 2 clinical trial will be confirmed in the phase 3 study.  If positive, entinostat would be the first epigenetic therapy to benefit patients with solid tumors, representing not only an important new treatment option for women with ER positive MBC but a significant commercial opportunity for Syndax."

    In addition to the breast cancer data, an abstract highlighting the immunomodulatory effects of entinostat entitled, "Phase I/II study of high-dose interleukin 2, aldesleukin, in combination with the histone deacetylase inhibitor entinostat in patients with metastatic renal cell carcinoma" will be presented in a poster session on Sunday, June 3 from 8:00 AM to 12:00 PM CT. 

    Breast Cancer and Hormone Therapy

    Approximately 230,000 new cases of invasive breast cancer are diagnosed in women annually in the Unite
    '/>"/>

    SOURCE Syndax Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
    2. Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
    3. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
    4. Syndax Pharmaceuticals Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
    5. Syndax Pharmaceuticals Entinostat in Combination Shows Activity in Breast Cancer
    6. Syndax Pharmaceuticals to Present at Biotech Showcase 2011
    7. Syndax Announces Publication of Entinostat NSCLC Data in Cancer Research
    8. Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
    9. Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
    10. Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat
    11. Syndax Pharmaceuticals Elects Arlene Morris to Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... Jan. 23, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the development and sale of patented biopharmaceutical medicine, ... pharmaceutical ingredients (API) today announced the business and development ... 1. Following the September 2014 JCM application ...
    (Date:1/22/2015)... (NYSE: RMD ) today announced results for its ... $423.0 million, a 10 percent increase compared to the quarter ... constant currency basis). Net income was $91.2 million, an increase ... 2013. Diluted earnings per share for the quarter were $0.64, ...
    (Date:1/22/2015)... 2015  Profil Institute for Clinical Research, Inc., a clinical ... today a new textbook,  Translational Research Methods for Diabetes, ... leading global scientific publisher. The textbook is ... use in early phase clinical studies of new drugs ...
    Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3
    (Date:1/22/2015)... 2015 AngelWeddingDress, the premier women’s dress ... wedding dresses. View website of AngelWeddingDress.com to ... maternity wedding dresses online for a bridal party. AngelWeddingDress ... quality for them. Its maternity wedding dresses are specially ...
    (Date:1/22/2015)... 22, 2015 Juvent Sports ( http://www.juventsports.com ... 2015 PGA Merchandise Show to bestow a Juvent Sports ... amateur golfer, Arlene McKitrick. The award commemorated and congratulated ... tournament win. She won her first amateur tournament in ...
    (Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo ... the federal multidistrict litigation underway in U.S. District Court, ... an Order dated January 20th, the Court has remanded ...
    (Date:1/22/2015)... 22, 2015 For over 20 years, Dr. David ... and Vista area has treated just about every type of ... circumstances. And for those same twenty-plus years, the team at ... those injuries with the best possible doctor. With the ...
    (Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television host, ... 32nd Annual Miami Breast Cancer Conference planned and ... , shares that “a fast-growing, virulent” cancer in her ... not followed up her clean mammogram with an ultrasound. ...
    Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
    ... September 2007. New Phase II data presented today suggest ... treatment of men with Hormone Resistant Prostate Cancer (HRPC), ... men with metastatic HRPC who were asymptomatic or mildly ... experienced a 45 percent reduction in the risk of ...
    ... - New CDA Web Site Offers Employers Resources to Help ... Disability -, PORTLAND, Maine, Sept. 25 Preparing for ... America,s,workforce, especially as the number of workers experiencing a disability,continues ... families struggle to,make ends meet due to an unforeseen stop ...
    ... Inc. (NYSE: BRL ) today confirmed that ... of the patents listed by,Sanofi- Aventis U.S. LLC ... 10mg. Barr,s Abbreviated New Drug Application (ANDA) ... product was received as acceptable,for filing by the ...
    ... A report from the American Cancer Society finds the breast cancer ... two percent per year, a trend that began in 1990 and ... report says African American women and women of other racial and ... that have led to those gains, and that a recent drop ...
    ... ST. LOUIS, Sept. 25 Shop ,n Save ... services in the St. Louis,area, has entered into ... wellness-based health insurance, to provide a wellness service,Vitality ... Plan(TM). Fully integrated with the insurance portion ...
    ... Inc. 5000, ... 100 & Deloitte Fast 50, PHILADELPHIA, Sept. 25 ... in the industry accolades,with three prestigious award wins in August ... Fast 50 and the Inc. 5000 lists all recognize Portico ...
    Cached Medicine News:Health News:Phase II study shows HRPC patients with bone metastases see improved survival with ZD4054 2Health News:Phase II study shows HRPC patients with bone metastases see improved survival with ZD4054 3Health News:Disabilities Rising Among Workers; Need for Employer-Driven Disability Awareness, Support Efforts Also Increases 2Health News:Disabilities Rising Among Workers; Need for Employer-Driven Disability Awareness, Support Efforts Also Increases 3Health News:Barr Confirms Patent Challenge of UROXATRAL(R) 2Health News:Barr Confirms Patent Challenge of UROXATRAL(R) 3Health News:American Cancer Society report finds breast cancer death rate continues to drop 2Health News:American Cancer Society report finds breast cancer death rate continues to drop 3Health News:American Cancer Society report finds breast cancer death rate continues to drop 4Health News:Shop 'n Save Pharmacy Helps Vitalize Members of Wellness-based Health Insurance Plan 2Health News:Shop 'n Save Pharmacy Helps Vitalize Members of Wellness-based Health Insurance Plan 3Health News:Portico Systems Wins Three Awards in 30 Days 2
    Cholesterol FS. For determination of cholesterol in serum or plasma. Available with Calibrator: Trucal U and Controls: Trulab N, Trulab P Trulab L....
    Intended for the quantitative determination of total cholesterol in serum. Reaction: Endpoint. Reaction complete within five minutes. Wavelength: 500 nm. Linearity: 700 mg/dL (18.1 mmol/L). Single st...
    This 16-bit integrated and cooled system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lighting....
    ... The ACS:180 SE is a ... PLUS, consisting of important physical ... simplify routine operation and increase ... the "Next Generation" ACS:180. The ...
    Medicine Products: